{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:35:45Z","timestamp":1790552145400,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1124\/jpet.107.124248","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:18:34Z","timestamp":1180732714000},"page":"1181-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug"],"prefix":"10.1016","volume":"322","author":[{"given":"Keiichi","family":"Kuwano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Hashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Asaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.124248_bib1","doi-asserted-by":"crossref","unstructured":"Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483: 285\u2013293.","DOI":"10.1016\/S1388-1981(99)00164-X"},{"key":"10.1124\/jpet.107.124248_bib2","doi-asserted-by":"crossref","unstructured":"Adie EJ, Mullaney I, McKenzie FR, and Milligan G (1992) Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma \u00d7 glioma cells to prostanoid agonists. Quantification and functional implications. Biochem J 285: 529\u2013536.","DOI":"10.1042\/bj2850529"},{"key":"10.1124\/jpet.107.124248_bib3","doi-asserted-by":"crossref","unstructured":"Armstrong RA (1996) Platelet prostanoid receptors. Pharmacol Ther 72: 171\u2013191.","DOI":"10.1016\/S0163-7258(96)00103-9"},{"key":"10.1124\/jpet.107.124248_bib4","doi-asserted-by":"crossref","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334: 296\u2013301.","DOI":"10.1056\/NEJM199602013340504"},{"key":"10.1124\/jpet.107.124248_bib5","doi-asserted-by":"crossref","unstructured":"Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927\u2013929.","DOI":"10.1038\/194927b0"},{"key":"10.1124\/jpet.107.124248_bib6","doi-asserted-by":"crossref","unstructured":"Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661\u2013690.","DOI":"10.1146\/annurev.pharmtox.41.1.661"},{"key":"10.1124\/jpet.107.124248_bib7","doi-asserted-by":"crossref","unstructured":"Chan KM and Jones RL (2004) Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol 43: 795\u2013807.","DOI":"10.1097\/00005344-200406000-00009"},{"key":"10.1124\/jpet.107.124248_bib8","doi-asserted-by":"crossref","unstructured":"Chow KB, Wong YH, and Wise H (2001) Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. Br J Pharmacol 134: 1375\u20131384.","DOI":"10.1038\/sj.bjp.0704388"},{"key":"10.1124\/jpet.107.124248_bib9","doi-asserted-by":"crossref","unstructured":"Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, and Tinker A (2002) Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 26: 194\u2013201.","DOI":"10.1165\/ajrcmb.26.2.4695"},{"key":"10.1124\/jpet.107.124248_bib10","doi-asserted-by":"crossref","unstructured":"Demolis JL, Robert A, Mouren M, Funck-Brentano C, and Jaillon P (1993) Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol 22: 711\u2013716.","DOI":"10.1097\/00005344-199311000-00007"},{"key":"10.1124\/jpet.107.124248_bib11","doi-asserted-by":"crossref","unstructured":"Hirsh PD, Campbell WB, Willerson JT, and Hillis LD (1981) Prostaglandins and ischemic heart disease. Am J Med 71: 1009\u20131026.","DOI":"10.1016\/0002-9343(81)90335-1"},{"key":"10.1124\/jpet.107.124248_bib12","doi-asserted-by":"crossref","unstructured":"Humbert M, Sitbon O, and Simonneau G (2004) Treatment of primary pulmonary hypertension. N Engl J Med 351: 1425\u20131436.","DOI":"10.1056\/NEJMra040291"},{"key":"10.1124\/jpet.107.124248_bib13","doi-asserted-by":"crossref","unstructured":"Jones RL, Qian YM, Chan KM, and Yim AP (1997) Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol 29: 525\u2013535.","DOI":"10.1097\/00005344-199704000-00015"},{"key":"10.1124\/jpet.107.124248_bib14","doi-asserted-by":"crossref","unstructured":"Jones RL, Qian YM, Chan KM, and Yim AP (1998) Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol 125: 1288\u20131296.","DOI":"10.1038\/sj.bjp.0702189"},{"key":"10.1124\/jpet.107.124248_bib15","doi-asserted-by":"crossref","unstructured":"Karpen CW, Pritchard KA Jr, Merola AJ, and Panganamala RV (1982) Alterations of the prostacyclin-thromboxane ratio in streptozotocin induced diabetic rats. Prostaglandins Leukot Med 8: 93\u2013103.","DOI":"10.1016\/S0262-1746(82)80001-2"},{"key":"10.1124\/jpet.107.124248_bib16","doi-asserted-by":"crossref","unstructured":"Kiriyama K, Ushikubi F, Kobayashi T, Hirata M, Sugimoto S, and Narumiya S (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122: 217\u2013224.","DOI":"10.1038\/sj.bjp.0701367"},{"key":"10.1124\/jpet.107.124248_bib17","doi-asserted-by":"crossref","unstructured":"Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DM, Jaxa-Chamiec AA, Kaumann AJ, Keen M, Kelly E, et al. (1991) Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 102: 251\u2013259.","DOI":"10.1111\/j.1476-5381.1991.tb12162.x"},{"key":"10.1124\/jpet.107.124248_bib18","doi-asserted-by":"crossref","unstructured":"Moncada S, Gryglewski S, Bunting S, and Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663\u2013665.","DOI":"10.1038\/263663a0"},{"key":"10.1124\/jpet.107.124248_bib19","doi-asserted-by":"crossref","unstructured":"Moncada S and Vane JR (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30: 293\u2013331.","DOI":"10.1016\/S0031-6997(25)06759-6"},{"key":"10.1124\/jpet.107.124248_bib20","doi-asserted-by":"crossref","unstructured":"Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678\u2013682.","DOI":"10.1038\/41780"},{"key":"10.1124\/jpet.107.124248_bib21","doi-asserted-by":"crossref","unstructured":"Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M, et al. (2000) Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102: 2005\u20132010.","DOI":"10.1161\/01.CIR.102.16.2005"},{"key":"10.1124\/jpet.107.124248_bib22","doi-asserted-by":"crossref","unstructured":"Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, and Narumiya S (1994) cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269: 9986\u20139992.","DOI":"10.1016\/S0021-9258(17)36979-X"},{"key":"10.1124\/jpet.107.124248_bib23","doi-asserted-by":"crossref","unstructured":"Narumiya S, Sugimoto Y, and Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193\u20131226.","DOI":"10.1152\/physrev.1999.79.4.1193"},{"key":"10.1124\/jpet.107.124248_bib24","doi-asserted-by":"crossref","unstructured":"Nilius SM, Hasse A, Kuger P, Schror K, and Meyer-Kirchrath J (2000) Agonistinduced long-term desensitization of the human prostacyclin receptor. FEBS Lett 484: 211\u2013216.","DOI":"10.1016\/S0014-5793(00)02156-6"},{"key":"10.1124\/jpet.107.124248_bib25","unstructured":"Nishio S, Yamada N, Endoh T, Isogaya M, Fukatsu Y, Nishimura S, Kanai N, and Umetsu T (1989) Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli. Arzneimittelforschung 39: 1229\u20131234."},{"key":"10.1124\/jpet.107.124248_bib26","doi-asserted-by":"crossref","unstructured":"Niwa T, Maeda K, and Shibata M (1987) Urinary prostaglandins and thromboxane in patients with chronic glomerulonephritis. Nephron 46: 281\u2013287.","DOI":"10.1159\/000184369"},{"key":"10.1124\/jpet.107.124248_bib27","doi-asserted-by":"crossref","unstructured":"Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, and Narumiya S (1995) In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116: 2828\u20132837.","DOI":"10.1111\/j.1476-5381.1995.tb15933.x"},{"key":"10.1124\/jpet.107.124248_bib28","doi-asserted-by":"crossref","unstructured":"Qian YM, Jones RL, Chan KM, Stock AI, and Ho JK (1994) Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol 113: 369\u2013374.","DOI":"10.1111\/j.1476-5381.1994.tb16997.x"},{"key":"10.1124\/jpet.107.124248_bib29","doi-asserted-by":"crossref","unstructured":"Smyth EM, Austin SC, Reilly MP, and FitzGerald GA (2000) Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 275: 32037\u201332045.","DOI":"10.1074\/jbc.M003873200"},{"key":"10.1124\/jpet.107.124248_bib30","doi-asserted-by":"crossref","unstructured":"Sobolewski A, Jourdan KB, Upton PD, Long L, and Morrell NW (2004) Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. Am J Physiol 287: L352\u2013L359.","DOI":"10.1152\/ajplung.00270.2003"},{"key":"10.1124\/jpet.107.124248_bib31","doi-asserted-by":"crossref","unstructured":"Toda N (1988) Beraprost sodium. Cardiovasc Drug Rev 6: 222\u2013238.","DOI":"10.1111\/j.1527-3466.1988.tb00378.x"},{"key":"10.1124\/jpet.107.124248_bib32","doi-asserted-by":"crossref","unstructured":"Todaka T, Yokoyama C, Yanamoto H, Hashimoto N, Nagata I, Tsukahara T, Hara S, Hatae T, Morishita R, Aoki M, et al. (1999) Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 30: 419\u2013426.","DOI":"10.1161\/01.STR.30.2.419"},{"key":"10.1124\/jpet.107.124248_bib33","doi-asserted-by":"crossref","unstructured":"Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, and Voelkel NF (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925\u20131932.","DOI":"10.1164\/ajrccm.159.6.9804054"},{"key":"10.1124\/jpet.107.124248_bib34","doi-asserted-by":"crossref","unstructured":"Ueno Y, Yamada N, Koike H, and Nishio S (1996) Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs. Gen Pharmacol 27: 333\u2013335.","DOI":"10.1016\/0306-3623(95)02007-1"},{"key":"10.1124\/jpet.107.124248_bib35","doi-asserted-by":"crossref","unstructured":"Vassaux G, Gaillard D, Ailhaud G, and Negrel R (1992) Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca2+-elevating agent. J Biol Chem 267: 11092\u201311097.","DOI":"10.1016\/S0021-9258(19)49879-7"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652434056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652434056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.124248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:23:26Z","timestamp":1739985806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652434056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S002235652434056X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.124248","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1087468.540514","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.124248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}